SCHEMBL1087642

SCHEMBL1087642

COC(=O)c1cc(C)on1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
HTT P42858 2/20 0.54
KDM4E B2RXH2 2/20 0.54
HPGD P15428 2/20 0.54
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
STAT3 P40763 1/20 0.53
TP53 P04637 3/20 0.51
ALDH1A1 P00352 2/20 0.50
GLA P06280 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 2/20 0.49
MAPK1 P28482 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6972500 0.82 MAPT (0.50) MAPTHTTKDM4EHPGDNPC1
SCHEMBL18280912 0.81 NPC1 (0.50) MAPTHTTKDM4EHPGDNPC1
SCHEMBL434805 0.80 MEN1 (0.61) MAPTKDM4EHPGDNPC1RAB9A
SCHEMBL160032 0.79 TP53 (0.51) MAPTHTTKDM4ESMN1; SMN2TP53
SCHEMBL28950613 0.79 NPC1 (0.49) MAPTHTTKDM4EHPGDNPC1
SCHEMBL27759338 0.79 RAB9A (0.49) MAPTHTTHPGDNPC1RAB9A
SCHEMBL8267185 0.79 NPC1 (0.53) MAPTHTTHPGDNPC1RAB9A
SCHEMBL27617928 0.78 MAPT (0.59) MAPTHTTKDM4ENPC1RAB9A
SCHEMBL29021918 0.78 MAPT (0.50) MAPTHTTKDM4EHPGDRAB9A
SCHEMBL31047148 0.78 TP53 (0.50) MAPTHTTKDM4ERAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 US disclosed
EP-4663630-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR LG Chem, Ltd. (KR) 2025-12-17 EP disclosed
EP-4622643-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-10-01 EP disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 US disclosed
EP-4252755-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2025-05-14 EP disclosed
CN-119998269-A Microbiocidal pyrazole derivatives 先正达农作物保护股份公司 2025-05-13 CN disclosed
US-20250084075-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2025-03-13 US disclosed
CN-119569706-A Therapeutic compounds 希四克斯探索有限公司 2025-03-07 CN disclosed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US disclosed
US-5002960-A Viricides for combating picornaviruses STERLING DRUG, INC. (US) 1991-03-26 US disclosed
EP-0413289-A2 Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents STERLING WINTHROP INC. (US) 1991-02-20 EP disclosed
US-4945164-A 1,3,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents and intermediates thereof STERLING DRUG INC. (US) 1990-07-31 US disclosed
US-4942241-A PICORNAVIRUS INCLUDING RHINOVIRUS STERLING DRUG INC. (US) 1990-07-17 US disclosed
US-4939267-A Viricides STERLING DRUG INC. (US) 1990-07-03 US disclosed
EP-0372470-A2 Novel alpha-cyano-beta-oxopropionamides CIBA-GEIGY AG (CH) 1990-06-13 EP disclosed
US-4843087-A OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES STERLING DRUG INC. (US) 1989-06-27 US disclosed
EP-0137242-A2 (Substituted) Phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof STERLING WINTHROP INC. (US) 1985-04-17 EP disclosed
EP-0111345-A2 Isoxazoles, useful as antiviral agents, and preparation thereof STERLING DRUG INC. (US) 1984-06-20 EP disclosed
US-4451476-A Isoxazoles as antiviral agents STERLING DRUG INC. (US) 1984-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 MAPT 1905/4885HTT 3933/4885KDM4E 2322/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB MAPT 1843/4885HTT 3484/4885KDM4E 1466/4885
US-20250084075-A1 THERAPEUTIC COMPOUNDS NFE2L2, KEAP1, NQO1 MAPT 572/4885HTT 282/4885KDM4E 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.